A Phase 3 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) and Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Macular Edema, sponsored by Bayer. Completed at 25 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-12.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 7th largest by enrollment, is one of 3 that started in 2013, is one of 11 in phase 3, and was the 9th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 3 started in 2013.
This study's enrollment of 381 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
16 studies in Macular Edema by Bayer: none open now, 1 under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Macular Edema by Bayer, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2013, is one of 7 in phase 3, and was the 5th registered.
Bayer’s Macular Edema studies by the year they started, since 2009.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
Among Bayer’s 16 in Macular Edema:
This tab as a report to print or save as PDF → With an account.
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular edema (DME) with central involvement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF \[vascular endothelial growth factor\] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.
Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.
Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.
Procedure: Macular Laser Photocoagulation
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)
Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. LOCF censored measurements after additional treatment.
Time frame: Baseline up to week 52
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
Time frame: Baseline up to week 52
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
Time frame: Baseline up to week 52
Percentage of Participants With a Greater Than Equal (>=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF
ETDRS DRSS: None (level 10); Mild to moderate nonproliferative diabetic retinopathy (DR) (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)
Time frame: Baseline up to week 52
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF
CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.
Time frame: Baseline up to week 52
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
Time frame: Baseline up to week 52
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.
Time frame: Baseline up to week 52
The study was conducted at centers in China, Hong Kong, South Korea, and Russian Federation between 18 February 2013 (first participant first visit) and 09 March 2015 (last participant last visit) (data cut-off date).
| Milestone | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Started | 127 | 127 | 127 |
| Participants received treatment | 127 | 127 | 124 |
| Completed | 122 | 116 | 117 |
| Not completed | 5 | 11 | 10 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 2 |
| Withdrew: Withdrawal of consent by participant | 1 | 3 | 4 |
| Withdrew: Adverse event | 4 | 5 | 4 |
Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. LOCF censored measurements after additional treatment.
| Letters correctly read | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF) | 13.7 ± 8.4 | 12.8 ± 9.5 | -0.2 ± 13.5 |
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
| Percentage of participants | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF | 70.9 | 62.7 | 23.4 |
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
| Percentage of participants | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF | 43.3 | 36.5 | 12.1 |
ETDRS DRSS: None (level 10); Mild to moderate nonproliferative diabetic retinopathy (DR) (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)
| Percentage of participants | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Percentage of Participants With a Greater Than Equal (>=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF | 60.7 | 62.3 | 21.7 |
CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.
| micrometer | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF | -238.7 ± 172.5 | -234.7 ± 160.8 | -109.3 ± 206.9 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
| Scores on a scale | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF | 6.65 ± 23.86 | 7.28 ± 22.95 | 0.04 ± 24.39 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.
| Scores on a scale | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF | 3.93 ± 22.36 | 10.25 ± 21.44 | 0.04 ± 23.14 |
Collected over From the start of study treatment up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravitreal Aflibercept Injection 2Q4 | — | 19/127 (15%) | 87/127 (68.5%) |
| Intravitreal Aflibercept Injection 2Q8 | — | 22/127 (17.3%) | 83/127 (65.4%) |
| Macular Laser Photocoagulation | — | 24/124 (19.4%) | 89/124 (71.8%) |
| Event | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Vitreous haemorrhageEye disorders | 1/127 | 0/127 | 4/124 |
| GlaucomaEye disorders | 0/127 | 0/127 | 2/124 |
| Visual acuity reducedEye disorders | 0/127 | 0/127 | 2/124 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/127 | 0/127 | 2/124 |
| Diabetic nephropathyRenal and urinary disorders | 0/127 | 1/127 | 2/124 |
| CataractEye disorders | 2/127 | 1/127 | 0/124 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/127 | 2/127 | 1/124 |
| Cerebral infarctionNervous system disorders | 2/127 | 2/127 | 0/124 |
| Nephrogenic anaemiaBlood and lymphatic system disorders | 1/127 | 0/127 | 1/124 |
| Acute myocardial infarctionCardiac disorders | 1/127 | 0/127 | 1/124 |
| Event | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation |
|---|---|---|---|
| Visual acuity reducedEye disorders | 12/127 | 14/127 | 24/124 |
| Conjunctival haemorrhageEye disorders | 18/127 | 13/127 | 6/124 |
| Diabetic retinal oedemaEye disorders | 17/127 | 13/127 | 15/124 |
| Retinal haemorrhageEye disorders | 14/127 | 17/127 | 12/124 |
| Visual acuity tests abnormalInvestigations | 9/127 | 3/127 | 15/124 |
| HypertensionVascular disorders | 10/127 | 15/127 | 8/124 |
| Retinal aneurysmEye disorders | 9/127 | 13/127 | 10/124 |
| Retinal exudatesEye disorders | 8/127 | 13/127 | 5/124 |
| Diabetes mellitusMetabolism and nutrition disorders | 12/127 | 10/127 | 11/124 |
| Macular oedemaEye disorders | 8/127 | 10/127 | 9/124 |
| Age, Continuous(years) | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation | Total |
|---|---|---|---|---|
| Mean | 59.3 ± 10.3 | 57.6 ± 10.1 | 58.8 ± 10.5 | 58.5 ± 10.3 |
| Sex: Female, Male(Participants) | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation | Total |
|---|---|---|---|---|
| Female | 68 | 60 | 60 | 188 |
| Male | 59 | 67 | 64 | 190 |
| Region of Enrollment(participants) | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation | Total |
|---|---|---|---|---|
| China | 101 | 101 | 99 | 301 |
| Russia | 10 | 10 | 9 | 29 |
| Other Asia-Pacific (Hong Kong, Korea) | 16 | 16 | 16 | 48 |
The record gives a start of Feb 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept